209 related articles for article (PubMed ID: 25873032)
1. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
Zoratti GL; Tanabe LM; Varela FA; Murray AS; Bergum C; Colombo É; Lang JE; Molinolo AA; Leduc R; Marsault E; Boerner J; List K
Nat Commun; 2015 Apr; 6():6776. PubMed ID: 25873032
[TBL] [Abstract][Full Text] [Related]
2. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Zoratti GL; Tanabe LM; Hyland TE; Duhaime MJ; Colombo É; Leduc R; Marsault E; Johnson MD; Lin CY; Boerner J; Lang JE; List K
Oncotarget; 2016 Sep; 7(36):58162-58173. PubMed ID: 27528224
[TBL] [Abstract][Full Text] [Related]
3. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Szabo R; Rasmussen AL; Moyer AB; Kosa P; Schafer JM; Molinolo AA; Gutkind JS; Bugge TH
Oncogene; 2011 Apr; 30(17):2003-16. PubMed ID: 21217780
[TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
5. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
6. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
[TBL] [Abstract][Full Text] [Related]
8. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation.
Lee SL; Huang PY; Roller P; Cho EG; Park D; Dickson RB
Mech Dev; 2010; 127(1-2):82-95. PubMed ID: 19853659
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
10. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
Ye F; Chen S; Liu X; Ye X; Wang K; Zeng Z; Su Y; Zhang XK; Zhou H
J Cell Mol Med; 2019 Jan; 23(1):155-166. PubMed ID: 30370662
[TBL] [Abstract][Full Text] [Related]
11. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.
Fan S; Ma YX; Gao M; Yuan RQ; Meng Q; Goldberg ID; Rosen EM
Mol Cell Biol; 2001 Aug; 21(15):4968-84. PubMed ID: 11438654
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
13. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
14. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Oberst M; Anders J; Xie B; Singh B; Ossandon M; Johnson M; Dickson RB; Lin CY
Am J Pathol; 2001 Apr; 158(4):1301-11. PubMed ID: 11290548
[TBL] [Abstract][Full Text] [Related]
15. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Cancer Res; 2007 May; 67(10):4869-77. PubMed ID: 17495323
[TBL] [Abstract][Full Text] [Related]
16. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Tervonen TA; Belitškin D; Pant SM; Englund JI; Marques E; Ala-Hongisto H; Nevalaita L; Sihto H; Heikkilä P; Leidenius M; Hewitson K; Ramachandra M; Moilanen A; Joensuu H; Kovanen PE; Poso A; Klefström J
Oncogene; 2016 Apr; 35(14):1832-46. PubMed ID: 26165838
[TBL] [Abstract][Full Text] [Related]
17. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Qiao H; Saulnier R; Patryzkat A; Rahimi N; Raptis L; Rossiter J; Tremblay E; Elliott B
Cell Growth Differ; 2000 Feb; 11(2):123-33. PubMed ID: 10714768
[TBL] [Abstract][Full Text] [Related]
18. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
[TBL] [Abstract][Full Text] [Related]
19. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
20. Strong expression association between matriptase and its substrate prostasin in breast cancer.
Bergum C; Zoratti G; Boerner J; List K
J Cell Physiol; 2012 Apr; 227(4):1604-9. PubMed ID: 21678412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
